Neuland Laboratories Ltd

BSE
NEULANDLAB •
BUY

1W Return

1M Return

6M Return

1Y Return

3Y Return

The current prices are delayed, login or open an account for live prices.
Start SIP in Neuland Laboratories Ltd
Stock Performance
52 Week Low - High
Today’s Low - High

Open

Prev. Close

Total Traded Value

View details of Market Depth
Fundamental

Market Cap (in crs)

Face Value

Turnover (in lacs)

Key Metrics
Qtr Change %
New 52W High today
24.4
TTM PE Ratio
Below industry Median
35.5
Price to Book Ratio
High in industry
8.3
Dividend yield 1yr %
Low in industry
0.2
TTM PEG Ratio
PEG TTM is less than 1
0.4
RSI
RSI Overbought
78.5
MFI
MFI strongly Overbought
83.3

Neuland Laboratories Ltd Key Financials

View more

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

Neuland Laboratories Ltd shareholding Pattern

Promoter
32.7%
Foreign Institutions
25.7%
Mutual Funds
4.1%
Domestic Institutions
6.8%
Public
34.8%
Promoter
32.7%
Foreign Institutions
24.4%
Mutual Funds
3.9%
Domestic Institutions
6.9%
Public
35.9%
Promoter
32.8%
Foreign Institutions
22.7%
Mutual Funds
1.8%
Domestic Institutions
6.4%
Public
38.1%
Promoter
36%
Foreign Institutions
21.6%
Mutual Funds
1.9%
Domestic Institutions
7.4%
Public
35.1%
Promoter
36%
Foreign Institutions
20.2%
Mutual Funds
1.6%
Domestic Institutions
7.2%
Public
36.6%
Promoter
36.1%
Foreign Institutions
18.1%
Mutual Funds
1%
Domestic Institutions
7.5%
Public
38.2%

Neuland Laboratories Ltd Technical Analysis

Moving Averages Analysis
Moving Averages Analysis
Current Price
Bullish Moving Averages
16
Bearish Moving Averages
0
5Day EMA
8,068.00
10Day EMA
7,871.10
12Day EMA
7,795.60
20Day EMA
7,535.40
26Day EMA
7,392.00
50Day EMA
7,075.10
100Day EMA
6,698.40
200Day EMA
5,937.60
5Day SMA
8,044.70
10Day SMA
7,869.00
20Day SMA
7,443.10
30Day SMA
7,064.40
50Day SMA
6,831.10
100Day SMA
6,796.40
150Day SMA
6,445.00
200Day SMA
5,942.80
Delivery & Volume
Resistance & Support
8,234.45
Pivot
Resistance
First Resistance
8,456.90
Second Resistance
8,621.25
Third Resistance
8,843.70
Support
First Support
8,070.10
Second support
7,847.65
Third Support
7,683.30
Relative Strength Index
78.51
Money Flow Index
83.33
MACD
403.60
MACD Signal
343.18
Average True Range
310.79
Average Directional Index
43.35
Rate of Change (21)
25.90
Rate of Change (125)
45.48
Peer comparison
Compare
Company
Market Price
Market Cap
52W Low
52W High
Caplin Point Laboratories Ltd.
11543.3
801.15
1617.8
Granules India Ltd.
12606.81
287.55
530.4
Jubilant Pharmova Ltd.
11503.85
319.3
780
Marksans Pharma Ltd.
8499.09
93.85
197.15
Procter & Gamble Health Ltd.
8479.03
4640.3
5640
Glenmark Life Sciences Ltd.
10342.52
582.8
970

Neuland Laboratories Ltd Company background

Founded in: 1984
Set up in 1984 as a private limited company to manufacture bulk drugs, Neuland Laboratories (NLL) is promoted by Davuluri Sucheth Rao. Neuland Drugs Pharmaceuticals Pvt Ltd, a company set up by the same promoters to manufacture bulk drugs was merged with NLL with effect from Apr.92. NLL manufactures bulk drugs such as salbutamol sulphate, terbutaline sulphate, labetalol hydrochloride and ciprofloxacin. The Company came out with its initial public offering in Apr.94 at a premium of Rs 35 aggregating Rs 5.69 cr, to partfinance the capacity expansion to manufacture bulk drugs and to diversify its productmix. The cost of the project as estimated by ICICI was Rs 15.7 cr.NLLs products are exported to more than 35 countries including Germany, Italy, Switzerland, the UK and the Netherlands. The company is also negotiating with multinational companies for tying up supplies of Ranitidine Hydrochloride Form I and Salbutamol Sulphate.During the year 19992000, the company introduced Itraconazole, an antifungal drug and Ipratropium Bromide, an antiasthmatic drug and the R D has developed a process for manufacture of Oflaxacin for Regulatory Markets. The Pashamylaram unit has received USFDA approval for manufacturing of Rantidine Hydrochloride Form.Mirtrazapine, an antidepressive drug and Ramipril a cardiovascular drug were introduced during the year 2001.The installed capacities of Ciprofloxacin and Ranitidine were increased with Rs.650 lacs financial assisitance from IDBI.The Company commenced commercial production of Ramipril, a cardiovascular drug for export to certain markets in 2002.The Company commenced commercial production of Citalopram Hydrobromide, an anti depressant, Pirbuterol Acetate, a bronchodilator, Levofloxacin, an anti bacterial, Levetiracetam, an anti convulsant in 2003.A subsidiary company of Neuland Laboratories Ltd was incorporated on January 4, 2007 in the State of Delaware, USA with its principal office in Orange County, California. During the year 20082009, Neuland Laboratories K.K., Japan was incorporated as a subsidiary of Company.During 201213, Company undertook a major reorganisation of businesses aimed at deleveraging on one hand and on other hand narrowing the focus on core activities: APIs, Intermediates and Contract Manufacturing. Consequently, the Company divested its RD activities by selling its Land and Building and some identified intellectual properties to Neuland Pharma Research Private Limited and its Peptides Research activities along with identified intellectual properties to Neuland Health Sciences Private Limited. It entered into a Joint Business Arrangement with API Corporation, Japan, a part of Mitsubishi Chemical, for manufacturing and sale of APIs and Intermediates.During 201314, the Company enhanced its product bouquet by launching 5 more products. It also enhanced its development portfolio to 22 molecules/ APIs created for launch between 2013 and 2016. It opened new office in New Jersey, provide them with quick support and coordinate in various business activities.In November 2016, the Board of Directors of the Company approved the Scheme of Amalgamation of Neuland Health Sciences Private Limited (Holding/ Parent Company) and Neuland Pharma Research Private Limited (fellow Subsidiary of the Holding Company) with the Company, as April 1, 2016, the Appointed Date of Scheme.The Company acquired multi product manufacturing facility Unit 3, with a capacity of about 197 kiloliters located at Gaddapotharam Village, in Sanga Reddy District, in December, 2017.
Read More

Neuland Laboratories Ltd FAQs

The past 1-year return of Neuland Laboratories Ltd [NEULANDLAB] share was 179.93. The Neuland Laboratories Ltd [NEULANDLAB] share hit a 1-year low of Rs. 2871.4 and a 1-year high of Rs. 8400.

The Mutual Fund Shareholding was 4.07% at the end of .

You can easily buy Neuland Laboratories Ltd shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

Open Demat Account
+91 -

personImage
Open Demat Account
+91 -